TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jul 22, 2021 20:26 JST
Source:
Sino Biopharmaceutical Limited
Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic
HONG KONG, Jul 22, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.
Henan province has been afflicted by the torrential rain storm and the severe flooding has drawn widespread concern. When a place is in trouble, help from all sides come to the rescue. With this thought in mind, Sino Biopharmaceutical, in fulfilling its social responsibility and living up to its role as a pharmaceutical company dedicated to healthcare, has donated both cash and emergency relief supplies each valued at RMB5 million via the Liaison Office of the Central People's Government in the Hong Kong S.A.R. These funds and supplies are to be used in supporting Henan province's efforts to provide emergency medical and rescue and relief services and prevent the emergence of an outbreak of disease or an epidemic in the wake of the devastation so as to protect the lives, safety and health of the public in Henan.
Ms. Cheng Cheung Ling, Vice Chairwoman and Executive Director of Sino Biopharmaceutical, said, "Capitalising on its professional strengths in the biopharmaceutical industry, the Group will closely monitor health issues and epidemic prevention preparations subsequent to this natural disaster, and donate supplies and medicines. Sino Biopharmaceutical regards safeguarding public health as its mission and responsibility. Let's stay together through thick and thin. Keep fighting and don't give up, Henan!"
About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for tumors, liver diseases, cardio-cerebral diseases, orthopedic diseases, respiratory system diseases and parenteral nutrition.
Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng China Enterprises Index, Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng SCHK Mainland China Healthcare Index, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index, etc.. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.
For more information:
Strategic Financial Relations Limited
Vicky Lee +852 2864 4834
vicky.lee@sprg.com.hk
Fanny Yuen +852 2864 4853
fanny.yuen@sprg.com.hk
Mandy Wong +852 2114 4900
mandy.wong@sprg.com.hk
Website: www.sprg.com.hk
Source: Sino Biopharmaceutical Limited
Sectors: BioTech
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Sino Biopharm (1177.HK) Announces 2024 Annual Results
March 20 2025 23:58 JST
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
August 14 2024 00:30 JST
Sino Biopharm (1177.HK) Announces 2023 Annual Results
March 29 2024 11:45 JST
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results
August 25 2023 19:12 JST
Sino Biopharm (1177.HK) Announces 2022 Annual Results
March 31 2023 21:11 JST
Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion
August 23 2022 19:51 JST
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
May 24 2021 17:12 JST
Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity
March 23 2021 17:09 JST
Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China
December 07 2020 08:55 JST
Sino Biopharmaceutical Announces 2020 Third Quarterly Results
November 30 2020 17:20 JST
More Press release >>
Latest Press Release
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Apr 01, 2025 12:25 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
Fujitsu and Macquarie University partner to help address critical shortage of machine learning engineers
Mar 31, 2025 09:28 JST
ForexIGO by Avenix Fzco Enhances Automated Trading with Dual-Asset Precision
Mar 29, 2025 22:30 JST
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 22:51 JST
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
NEC and COEDO Brewery develop the second edition of "The taste of life created by brewers and AI -- Agentic AI x Craft Beer"
Mar 28, 2025 13:08 JST
More Latest Release >>